Summary
Global Markets Direct’s, ‘Endometrial Cancer - Pipeline Review, H1 2016’, provides an overview of the Endometrial Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Endometrial Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer
- The report reviews pipeline therapeutics for Endometrial Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Endometrial Cancer therapeutics and enlists all their major and minor projects
- The report assesses Endometrial Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Endometrial Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Ability Pharmaceuticals, S.L.
Advenchen Laboratories, LLC
Aeterna Zentaris Inc.
Arno Therapeutics, Inc.
ArQule, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
BeiGene, Ltd.
BioNTech AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cellceutix Corporation
Critical Outcome Technologies Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Esperance Pharmaceuticals, Inc.
Exelixis, Inc.
Galena Biopharma, Inc.
Genmab A/S
GlaxoSmithKline Plc
Gradalis Inc.
Horizon Pharma Plc
ImmunoGen, Inc.
Incyte Corporation
Karyopharm Therapeutics, Inc.
Medivation, Inc.
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Novartis AG
OncoHoldings, Inc.
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Pharma Mar, S.A.
Pharmsynthez
Pivot Pharmaceuticals Inc
Puma Biotechnology, Inc.
Sanofi
Shenogen Pharma Group Ltd.
Synthon Holdings BV
Vertex Pharmaceuticals Incorporated
Vyriad
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Endometrial Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Endometrial Cancer - Overview 10
Pipeline Products for Endometrial Cancer - Comparative Analysis 11
Endometrial Cancer - Therapeutics under Development by Companies 12
Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes 15
Endometrial Cancer - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Endometrial Cancer - Products under Development by Companies 19
Endometrial Cancer - Products under Investigation by Universities/Institutes 23
Endometrial Cancer - Companies Involved in Therapeutics Development 24
Ability Pharmaceuticals, S.L. 24
Advenchen Laboratories, LLC 25
Aeterna Zentaris Inc. 26
Arno Therapeutics, Inc. 27
ArQule, Inc. 28
AstraZeneca Plc 29
AVEO Pharmaceuticals, Inc. 30
BeiGene, Ltd. 31
BioNTech AG 32
Boehringer Ingelheim GmbH 33
Bristol-Myers Squibb Company 34
Cellceutix Corporation 35
Critical Outcome Technologies Inc. 36
Eisai Co., Ltd. 37
Eli Lilly and Company 38
Esperance Pharmaceuticals, Inc. 39
Exelixis, Inc. 40
Galena Biopharma, Inc. 41
Genmab A/S 42
GlaxoSmithKline Plc 43
Gradalis Inc. 44
Horizon Pharma Plc 45
ImmunoGen, Inc. 46
Incyte Corporation 47
Karyopharm Therapeutics, Inc. 48
Medivation, Inc. 49
Merck & Co., Inc. 50
Merck KGaA 51
Millennium Pharmaceuticals, Inc. 52
Novartis AG 53
OncoHoldings, Inc. 54
Otsuka Holdings Co., Ltd. 55
Pfizer Inc. 56
Pharma Mar, S.A. 57
Pharmsynthez 58
Pivot Pharmaceuticals Inc 59
Puma Biotechnology, Inc. 60
Sanofi 61
Shenogen Pharma Group Ltd. 62
Synthon Holdings BV 63
Vertex Pharmaceuticals Incorporated 64
Vyriad 65
Endometrial Cancer - Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Combination Products 67
Assessment by Target 68
Assessment by Mechanism of Action 73
Assessment by Route of Administration 77
Assessment by Molecule Type 79
Drug Profiles 81
²¹²Pb-TCMC-Trastuzumab - Drug Profile 81
ABTL-0812 - Drug Profile 83
AEZS-125 - Drug Profile 85
AL-3818 - Drug Profile 86
ARQ-092 - Drug Profile 88
AV-203 - Drug Profile 90
AZD-2014 - Drug Profile 92
AZD-5363 - Drug Profile 94
BGB-283 - Drug Profile 96
buparlisib hydrochloride - Drug Profile 98
cabozantinib s-malate - Drug Profile 102
Cellular Immunotherapy for Oncology - Drug Profile 107
Cellular Immunotherapy for Ovarian and Endometrial Cancer - Drug Profile 108
Cellular Immunotherapy to Taregt HER-2 for Oncology - Drug Profile 109
COTI-2 - Drug Profile 110
cridanimod - Drug Profile 113
DT-1154 - Drug Profile 114
EP-200 - Drug Profile 115
epacadostat - Drug Profile 116
everolimus - Drug Profile 118
GALE-301 - Drug Profile 125
gemogenovatucel-T - Drug Profile 127
GSK-2636771 - Drug Profile 129
HO-3867 - Drug Profile 130
INCB-50465 - Drug Profile 131
INCB-54828 - Drug Profile 132
interferon gamma-1b - Drug Profile 133
itacitinib adipate - Drug Profile 136
KM-3174 - Drug Profile 138
lenvatinib mesylate - Drug Profile 142
lurbinectedin - Drug Profile 149
LY-3023414 - Drug Profile 153
mirvetuximab soravtansine - Drug Profile 155
MK-2206 - Drug Profile 157
Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - Drug Profile 160
neratinib - Drug Profile 161
nintedanib - Drug Profile 166
onapristone ER - Drug Profile 172
ONCO-101 - Drug Profile 174
Oncolytic Virus to Activate IFNb for Endometrial Cancer - Drug Profile 175
Oncolytic Virus to Target CD46 for Gynecological Cancers and Urinary Tract Cancer - Drug Profile 176
OPB-111001 - Drug Profile 178
Peptides to Inhibit GnRH II Receptor for Oncology - Drug Profile 179
PF-06671008 - Drug Profile 180
pimasertib hydrochloride + voxtalisib - Drug Profile 181
PVT-005 - Drug Profile 183
sapanisertib - Drug Profile 184
SAR-408701 - Drug Profile 186
selinexor - Drug Profile 187
sirolimus albumin-bound - Drug Profile 193
Small Molecules to Inhibit Skp2 for Endometrial Cancer and Melanoma - Drug Profile 195
SNG-1153 - Drug Profile 196
SP-2509 - Drug Profile 197
SYD-985 - Drug Profile 199
talazoparib - Drug Profile 201
tisotumab vedotin - Drug Profile 204
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 206
uprosertib - Drug Profile 208
VX-984 - Drug Profile 210
X-480 - Drug Profile 211
zoptarelin doxorubicin - Drug Profile 212
Endometrial Cancer - Recent Pipeline Updates 214
Endometrial Cancer - Dormant Projects 328
Endometrial Cancer - Discontinued Products 331
Endometrial Cancer - Product Development Milestones 332
Featured News & Press Releases 332
Appendix 340
Methodology 340
Coverage 340
Secondary Research 340
Primary Research 340
Expert Panel Validation 340
Contact Us 340
Disclaimer 341
List of Tables
Number of Products under Development for Endometrial Cancer, H1 2016 14
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Number of Products under Development by Companies, H1 2016 (Contd..1) 17
Number of Products under Development by Companies, H1 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2016 19
Comparative Analysis by Late Stage Development, H1 2016 20
Comparative Analysis by Clinical Stage Development, H1 2016 21
Comparative Analysis by Early Stage Development, H1 2016 22
Products under Development by Companies, H1 2016 23
Products under Development by Companies, H1 2016 (Contd..1) 24
Products under Development by Companies, H1 2016 (Contd..2) 25
Products under Development by Companies, H1 2016 (Contd..3) 26
Products under Investigation by Universities/Institutes, H1 2016 27
Endometrial Cancer - Pipeline by Ability Pharmaceuticals, S.L., H1 2016 28
Endometrial Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 29
Endometrial Cancer - Pipeline by Aeterna Zentaris Inc., H1 2016 30
Endometrial Cancer - Pipeline by Arno Therapeutics, Inc., H1 2016 31
Endometrial Cancer - Pipeline by ArQule, Inc., H1 2016 32
Endometrial Cancer - Pipeline by AstraZeneca Plc, H1 2016 33
Endometrial Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 34
Endometrial Cancer - Pipeline by BeiGene, Ltd., H1 2016 35
Endometrial Cancer - Pipeline by BioNTech AG, H1 2016 36
Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 37
Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 38
Endometrial Cancer - Pipeline by Cellceutix Corporation, H1 2016 39
Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 40
Endometrial Cancer - Pipeline by Eisai Co., Ltd., H1 2016 41
Endometrial Cancer - Pipeline by Eli Lilly and Company, H1 2016 42
Endometrial Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016 43
Endometrial Cancer - Pipeline by Exelixis, Inc., H1 2016 44
Endometrial Cancer - Pipeline by Galena Biopharma, Inc., H1 2016 45
Endometrial Cancer - Pipeline by Genmab A/S, H1 2016 46
Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 47
Endometrial Cancer - Pipeline by Gradalis Inc., H1 2016 48
Endometrial Cancer - Pipeline by Horizon Pharma Plc, H1 2016 49
Endometrial Cancer - Pipeline by ImmunoGen, Inc., H1 2016 50
Endometrial Cancer - Pipeline by Incyte Corporation, H1 2016 51
Endometrial Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 52
Endometrial Cancer - Pipeline by Medivation, Inc., H1 2016 53
Endometrial Cancer - Pipeline by Merck & Co., Inc., H1 2016 54
Endometrial Cancer - Pipeline by Merck KGaA, H1 2016 55
Endometrial Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 56
Endometrial Cancer - Pipeline by Novartis AG, H1 2016 57
Endometrial Cancer - Pipeline by OncoHoldings, Inc., H1 2016 58
Endometrial Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 59
Endometrial Cancer - Pipeline by Pfizer Inc., H1 2016 60
Endometrial Cancer - Pipeline by Pharma Mar, S.A., H1 2016 61
Endometrial Cancer - Pipeline by Pharmsynthez, H1 2016 62
Endometrial Cancer - Pipeline by Pivot Pharmaceuticals Inc, H1 2016 63
Endometrial Cancer - Pipeline by Puma Biotechnology, Inc., H1 2016 64
Endometrial Cancer - Pipeline by Sanofi, H1 2016 65
Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd., H1 2016 66
Endometrial Cancer - Pipeline by Synthon Holdings BV, H1 2016 67
Endometrial Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 68
Endometrial Cancer - Pipeline by Vyriad, H1 2016 69
Assessment by Monotherapy Products, H1 2016 70
Assessment by Combination Products, H1 2016 71
Number of Products by Stage and Target, H1 2016 73
Number of Products by Stage and Mechanism of Action, H1 2016 78
Number of Products by Stage and Route of Administration, H1 2016 82
Number of Products by Stage and Molecule Type, H1 2016 84
Endometrial Cancer Therapeutics - Recent Pipeline Updates, H1 2016 218
Endometrial Cancer - Dormant Projects, H1 2016 332
Endometrial Cancer - Dormant Projects (Contd..1), H1 2016 333
Endometrial Cancer - Dormant Projects (Contd..2), H1 2016 334
Endometrial Cancer - Discontinued Products, H1 2016 335
List of Figures
Number of Products under Development for Endometrial Cancer, H1 2016 14
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Number of Products under Investigation by Universities/Institutes, H1 2016 19
Comparative Analysis by Clinical Stage Development, H1 2016 21
Comparative Analysis by Early Stage Products, H1 2016 22
Assessment by Monotherapy Products, H1 2016 70
Assessment by Combination Products, H1 2016 71
Number of Products by Top 10 Targets, H1 2016 72
Number of Products by Stage and Top 10 Targets, H1 2016 72
Number of Products by Top 10 Mechanism of Actions, H1 2016 77
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 77
Number of Products by Top 10 Routes of Administration, H1 2016 81
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 81
Number of Products by Top 10 Molecule Types, H1 2016 83
Number of Products by Stage and Top 10 Molecule Types, H1 2016 83
